Table 4.
Assessment of the gene expression levels of cGAS and STING and plasma levels of the investigated cytokines according to the number of symptoms and the presence and absence of comorbidities in the group with long COVID.
| Variables | cGAS (RQ) | STING (RQ) | IFN-α (pg/mL) | TNF-α (pg/mL) | IL-6 (pg/mL) |
|---|---|---|---|---|---|
| Median (IIQ) | Median (IIQ) | Median (IIQ) | Median (IIQ) | Median (IIQ) | |
| Number of symptoms | |||||
| 2 a 4 | 0.28 (0.45) | 0.05 (0.29) | 1.90 (7.14) | 8.24 (2.26) | 7.85 (0.64) |
| 5 a 7 | 0.72 (1.50) | 0.19 (0.74) | 10.50 (17.90) | 8.56 (2.88) | 8.42 (2.94) |
| 8 a 10 | 0.35 (0.19) | 0.18 (0.80) | 21.30 (19.37) | 8.24 (2.26) | 7.70 (2.49) |
| p | 0.5080 | 0.6097 | 0.4342 | 0.9857 | 0.8519 |
| Comorbidities | |||||
| Present | 0.242 (0.43) | 0.139 (0.17) | 4.62 (12.12) | 8.01 (1.69) | 8.06 (3.12) |
| Absent | 0.437 (1.94) | 0.297 (0.97) | 11.70 (21.60) | 8.96 (2.67) | 8.01 (1.75) |
| p | 0.2382 | 0.3541 | 0.5474 | 0.9899 | 0.8739 |
IIQ: interquartile range. Comorbidities: diabetes mellitus, chronic cardiovascular disease, obesity, chronic kidney disease.